Sun's so-long wave to Tipperary: Indian firm to close Ranbaxy plant this year

By Gareth Macdonald

- Last updated on GMT

Ranbaxy plant in Cashel, Ireland to close (source: Google)
Ranbaxy plant in Cashel, Ireland to close (source: Google)
Sun Pharmaceuticals has confirmed it will close a Ranbaxy Laboratories facility in Ireland by the end of the year.

Sun told us “The Cashel facility closure is being implemented as part of this plan to right size our company’s global manufacturing activities. We expect to cease operations at Cashel by end of current calendar year​.

As part of the unit’s closure process, we will move some laboratory roles to other facilities within Sun Pharma’s global operations’ network​.”

The Indian drug firm first mooted winding up operations last September​. At the time it said it needed to optimize its manufacturing network following its acquisition of Ranbaxy​.

According to IDA Ireland - the Government agency that is responsible for industrial development in the country – the facility manufactures finished drug products.

Union response

Tony Kelly from Unite, the trade union that represents 70 of the 100 people currently employed at the Cashel site, described the news as a blow for the town and the region.

Unite is very disappointed that Ranbaxy parent Sun Pharma has decided to close the Cashel plant having failed to find a buyer, especially as it is less than 12 months since the acquisition was made​. “

Ranbaxy declined to comment when asked if it had sought a buyer for the facility.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars